TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7573299

Group type: EXPERIMENTAL
Intervention: Apraclonidine hydrochloride 0.5%
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo (apraclonidine's vehicle)
Number of subjects: 174
Study: 1967534

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg twice daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 14
Study: 7030632

Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 77

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 77
Study: 31882409

Group type: EXPERIMENTAL
Intervention: Once-weekly exenatide therapy
Number of subjects: 14752

Group type: EXPERIMENTAL
Intervention: Severe hypoglycemic events (SHEs)
Number of subjects: 14752

Group type: EXPERIMENTAL
Intervention: Nonfatal cardiovascular events (nonfatal MI, nonfatal stroke, hACS, hHF)
Number of subjects: 14752
Study: 30777794

Group type: COMPARATOR
Intervention: TP (thalidomide 100 mg/d for ≤12 months/until disease progression; prednisolone 50 mg on alternate days indefinitely/until disease progression; n=100)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: VTP (subcutaneous bortezomib 1.3 mg/m2 every 2 weeks for 32 weeks, plus TP; n=103)
Number of subjects: 203
Study: 28658357

Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion (RME)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Slow Maxillary Expansion (SME)
Number of subjects: 37
Study: 25814432

Group type: EXPERIMENTAL
Intervention: Normal Glucose Tolerance (NGT) with Hypertension
Number of subjects: 1489

Group type: EXPERIMENTAL
Intervention: Isolated Impaired Fasting Glucose (IFG) with Hypertension
Number of subjects: 1489

Group type: EXPERIMENTAL
Intervention: Isolated Impaired Glucose Tolerance (IGT) with Hypertension
Number of subjects: 1489

Group type: EXPERIMENTAL
Intervention: Combined IFG/IGT with Hypertension
Number of subjects: 1489

Group type: COMPARATOR
Intervention: Normal Glucose Tolerance (NGT) without Hypertension
Number of subjects: 1489

Group type: COMPARATOR
Intervention: Isolated Impaired Fasting Glucose (IFG) without Hypertension
Number of subjects: 1489

Group type: COMPARATOR
Intervention: Isolated Impaired Glucose Tolerance (IGT) without Hypertension
Number of subjects: 1489

Group type: COMPARATOR
Intervention: Combined IFG/IGT without Hypertension
Number of subjects: 1489
Study: 24051063

Group type: EXPERIMENTAL
Intervention: HIV/HCV educational intervention
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: HIV questionnaire
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: HIV questionnaire individual items
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: HCV questionnaire individual items
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Self-reported likelihood of using a condom
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Self-reported risk behaviors
Number of subjects: 54
Study: 20336486

Group type: EXPERIMENTAL
Intervention: HIV prevention intervention
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 79
Study: 20812442

Group type: EXPERIMENTAL
Intervention: ACOG guidelines
Number of subjects: 81

Group type: COMPARATOR
Intervention: EAST guidelines
Number of subjects: 81
Study: 19275854

Group type: EXPERIMENTAL
Intervention: 21‐mm circular‐stapler
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 45‐mm linear‐stapler
Number of subjects: 80

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 80
Study: 16076335

Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum (10 mmHg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: High-pressure pneumoperitoneum (15 mmHg)
Number of subjects: 53
Study: 11978956

Group type: EXPERIMENTAL
Intervention: Metoprolol sustained-release treatment
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 10421878

Group type: EXPERIMENTAL
Intervention: ChAT and VAChT immunopositive neurons in the nucleus basalis of Meynert (nbM)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: ChAT and VAChT immunopositive neurons
Number of subjects: 3
Study: 8574276

Group type: EXPERIMENTAL
Intervention: Auricular acupressure device
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo acupressure device for wrist
Number of subjects: 96
Study: 2275356

Group type: EXPERIMENTAL
Intervention: Oral metyrapone tartrate
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 8
Study: 7314361

Group type: EXPERIMENTAL
Intervention: Latex catheters
Number of subjects: 100

Group type: COMPARATOR
Intervention: Teflon catheters
Number of subjects: 100
Study: 30244181

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (∼16 mmol nitrate per day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 27644437

Group type: EXPERIMENTAL
Intervention: Safety Attitudes Questionnaire (SAQ)
Number of subjects: 420
Study: 23813562

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Wait list-control
Number of subjects: 46
Study: 22274169

Group type: EXPERIMENTAL
Intervention: GA plus TEA (TEA(perio) group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: GA alone (TEA(post) group)
Number of subjects: 64
Study: 20357728

Group type: EXPERIMENTAL
Intervention: Direct stripping of cystic wall from the initial adhesion site (group A)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Circular excision of ovarian tissue around the initial adhesion site and then stripping (group B)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Both techniques (group A and group B)
Number of subjects: 92
Study: 18558914

Group type: EXPERIMENTAL
Intervention: Coordinated care plan including treatment for depression and anxiety disorders, containment strategy for somatisation, and service coordinator-assisted self-management.
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard treatment (Control group)
Number of subjects: 124
Study: 16375964

Group type: EXPERIMENTAL
Intervention: Whitening gel containing hydrogen peroxide and sodium percarbonate formulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 12
Study: 12524411

Group type: EXPERIMENTAL
Intervention: 0.1% GTN ointment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.2% GTN ointment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.4% GTN ointment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 200
Study: 10645233

Group type: EXPERIMENTAL
Intervention: Isolator 10 blood culture system
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Pour plate method
Number of subjects: 71

Group type: COMPARATOR
Intervention: Conventional broth based blood cultures
Number of subjects: 71
Study: 8712446

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.25 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.50 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 30
Study: 2014460

Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.45 mg/kg
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam 0.15 mg/kg
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Oral trimeprazine tartrate 2 mg/kg, methadone 0.1 mg/kg, droperidol 0.15 mg/kg (TMD)
Number of subjects: 135

Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 135
Study: 7018788

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 31478148

Group type: EXPERIMENTAL
Intervention: rt‐PA + hesperidin
Number of subjects: 2

Group type: COMPARATOR
Intervention: rt‐PA + placebo (Pc)
Number of subjects: 2
Study: 30993350

Group type: EXPERIMENTAL
Intervention: Deep extubation in the lateral position (group L)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Deep extubation in the supine position (group S)
Number of subjects: 92
Study: 28750955

Group type: EXPERIMENTAL
Intervention: Counterstrain
Number of subjects: 22

Group type: COMPARATOR
Intervention: Spinal manipulation
Number of subjects: 22
Study: 25947235

Group type: EXPERIMENTAL
Intervention: Talc pleurodesis (group A)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Povidone-iodine pleurodesis (group B)
Number of subjects: 39
Study: 24062327

Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg once daily
Number of subjects: 1261

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1261

Group type: EXPERIMENTAL
Intervention: linagliptin
Number of subjects: 1261
Study: 20799264

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 200 mg every other week plus methotrexate
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo plus methotrexate
Number of subjects: 392
Study: 19740044

Group type: EXPERIMENTAL
Intervention: Ongoing half‐yearly monitoring of COPD patients with respiratory expert recommendations for the GP
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 17045670

Group type: EXPERIMENTAL
Intervention: Tissue Doppler of mitral annulus
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tissue Doppler of tricuspid annulus
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tissue Doppler derived left ventricular and right ventricular measurements
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tricuspid inflow E velocity and E(m) ratio
Number of subjects: 36
Study: 15309011

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 888

Group type: COMPARATOR
Intervention: No ACE inhibitors (Control)
Number of subjects: 888
Study: 11730570

Group type: EXPERIMENTAL
Intervention: +Trans-T
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: -Trans-T
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: +M1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: -M1
Number of subjects: 12
Study: 9491017

Group type: EXPERIMENTAL
Intervention: Parent-child autotutorial group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Counseling group
Number of subjects: 0

Group type: COMPARATOR
Intervention: At-risk control group
Number of subjects: 0
Study: 7887119

Group type: EXPERIMENTAL
Intervention: Clonidine (4 micrograms.kg‐1 loading dose in 30 min, maintained with 1 microgram.kg‐1.h‐1 infusion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Labetalol (0.2 mg.kg‐1 loading dose followed by 0.1 mg.kg‐1.h‐1 infusion)
Number of subjects: 20
Study: 3369996

Group type: EXPERIMENTAL
Intervention: Primary capsulotomy group
Number of subjects: 162

Group type: COMPARATOR
Intervention: Capsule intact group
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Both groups (including nonrandomized cases)
Number of subjects: 162
Study: 30339244

Group type: EXPERIMENTAL
Intervention: 50% reduced individualized GH dose (GHRID; n = 27; 20 boys)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Unchanged individualized GH dose (GHUID; n = 38; 27 boys)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard weight-based dose (GHFIX; n = 33; 25 boys)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: GHRID group
Number of subjects: 98

Group type: COMPARATOR
Intervention: GHUID group
Number of subjects: 98

Group type: COMPARATOR
Intervention: GHFIX group
Number of subjects: 98
Study: 28185715

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 886

Group type: COMPARATOR
Intervention: Control (non-OAD)
Number of subjects: 886
Study: 26192975

Group type: EXPERIMENTAL
Intervention: Creatine (1 g/d)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo (dextrose at same dose)
Number of subjects: 109
Study: 23223105

Group type: EXPERIMENTAL
Intervention: Lidocaine 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lidocaine 45 mg
Number of subjects: 0
Study: 22108476

Group type: EXPERIMENTAL
Intervention: Meriva (curcumin phytosome) at a dosage of 1 g/day (two tablets/day) for four weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Best possible management (control group)
Number of subjects: 25
Study: 19619673

Group type: EXPERIMENTAL
Intervention: Dopamine (3 microg kg(‐1)min(‐1))
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 16966348

Group type: EXPERIMENTAL
Intervention: Ganirelix acetate
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group (no ganirelix acetate)
Number of subjects: 174
Study: 15550800

Group type: EXPERIMENTAL
Intervention: Enhanced care intervention for depression management over 24 months
Number of subjects: 326

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 326
Study: 11309016

Group type: EXPERIMENTAL
Intervention: Intavent tube
Number of subjects: 54

Group type: COMPARATOR
Intervention: Mallinckrodt reinforced tube
Number of subjects: 54

Group type: COMPARATOR
Intervention: Portex Blue Line tube
Number of subjects: 54
Study: 9164316

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 1265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1265
Study: 7696451

Group type: EXPERIMENTAL
Intervention: Low viscosity budesonide enema (2 mg/100 mL)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High viscosity budesonide enema (2 mg/100 mL)
Number of subjects: 5
Study: 2821947

Group type: EXPERIMENTAL
Intervention: Higher dosages of enalapril (40 and, if necessary 60 mg once‐a‐day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Enalapril 20 mg and hydrochlorothiazide 25 and, if necessary, 50 mg once‐a‐day
Number of subjects: 46
Study: 29325913

Group type: EXPERIMENTAL
Intervention: CLIPP module (Computer‐Assisted Learning in Pediatrics Program)
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Faculty-led case presentation feedback session
Number of subjects: 789

Group type: COMPARATOR
Intervention: Control (neither intervention)
Number of subjects: 789
Study: 26096889

Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac sodium 18.75 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac sodium 37.5 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Oral diclofenac potassium 50 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 24438902

Group type: EXPERIMENTAL
Intervention: Dendritic cell immunotherapy (6 doses intravenous over 14 weeks)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Dendritic cell immunotherapy
Number of subjects: 51
Study: 23519586

Group type: EXPERIMENTAL
Intervention: (Pyr(1))apelin‐13 infusion (0.3‐3.0 nmol/min for local and 30‐300 nmol/min for systemic infusion)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prolonged systemic (Pyr(1))apelin‐13 infusion (30 nmol/min for 6 hours)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: (Pyr(1))apelin‐13 infusion during sodium depletion and angiotensin II coinfusion
Number of subjects: 60
Study: 20505173

Group type: EXPERIMENTAL
Intervention: Carotid-artery stenting
Number of subjects: 2502

Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 2502
Study: 18782484

Group type: EXPERIMENTAL
Intervention: Diet plus protein-calorie supplementation (formula providing 250 kcal + 20 g protein)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 48
Study: 16882533

Group type: EXPERIMENTAL
Intervention: Asbestos exposure among those >or=65 years of age who had worked for the vermiculite mining company
Number of subjects: 7307

Group type: EXPERIMENTAL
Intervention: Asbestos exposure while in the military
Number of subjects: 7307

Group type: EXPERIMENTAL
Intervention: Occupational exposure to vermiculite
Number of subjects: 7307

Group type: EXPERIMENTAL
Intervention: Frequent contact with vermiculite through various exposure pathways
Number of subjects: 7307

Group type: EXPERIMENTAL
Intervention: Increasing numbers of reported vermiculite exposure pathways
Number of subjects: 7307
Study: 12927639

Group type: EXPERIMENTAL
Intervention: Combined therapy with pulsed ultrasound and interferential current (CTPI)
Number of subjects: 17

Group type: COMPARATOR
Intervention: SHAM procedure
Number of subjects: 17
Study: 11179104

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 68
Study: 9757976

Group type: EXPERIMENTAL
Intervention: Bloodless cesarean section
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (vaginal delivery or routine cesarean section)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Bloodless cesarean section (excluding zidovudine users)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (excluding zidovudine users)
Number of subjects: 108
Study: 8091436

Group type: EXPERIMENTAL
Intervention: Cox proportional-hazards model
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Cox proportional-hazards model applied to validation sample
Number of subjects: 492

Group type: COMPARATOR
Intervention: Subtypes of stroke
Number of subjects: 492
Study: 3395493

Group type: EXPERIMENTAL
Intervention: Five-session dietary change program
Number of subjects: 218

Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 218
Study: 29438200

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine
Number of subjects: 310

Group type: COMPARATOR
Intervention: ABC/lamivudine (ABC/3TC)
Number of subjects: 310
Study: 28019683

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg QD
Number of subjects: 224

Group type: COMPARATOR
Intervention: Risedronate 35 mg QW
Number of subjects: 224
Study: 25231069

Group type: EXPERIMENTAL
Intervention: Sonic scaler (AIR)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ultrasonic scaler (TIG)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hand instruments (GRA)
Number of subjects: 11
Study: 23066999

Group type: EXPERIMENTAL
Intervention: Print ad focused on depression
Number of subjects: 271

Group type: COMPARATOR
Intervention: Nonrelevant comparison ad
Number of subjects: 271
Study: 21429222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 18419399

Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine
Number of subjects: 0
Study: 17168358

Group type: EXPERIMENTAL
Intervention: Combined treatment (radical surgery plus pre- and intraoperative radiotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study: 14581425

Group type: EXPERIMENTAL
Intervention: Vaccination with GM-CSF in adjuvant
Number of subjects: 26

Group type: COMPARATOR
Intervention: Vaccination with dendritic cells (DCs)
Number of subjects: 26
Study: 10881246

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) 30-46 mg/kg/day orally
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC)
Number of subjects: 267
Study: 8695025

Group type: EXPERIMENTAL
Intervention: Dinamap 845XT automatic blood pressure monitor
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Dinamap 8100 automatic blood pressure monitor
Number of subjects: 417

Group type: COMPARATOR
Intervention: Mercury sphygmomanometers
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Dinamap 845XT
Number of subjects: 417
Study: 1565181

Group type: EXPERIMENTAL
Intervention: 24,25-dihydroxycholecalciferol (10 micrograms daily for 3 months)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31858840

Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy-ALA following fractional CO2 Laser
Number of subjects: 10
Study: 31808404

Group type: EXPERIMENTAL
Intervention: Two-shift operation mode
Number of subjects: 92

Group type: COMPARATOR
Intervention: Single player mode
Number of subjects: 92
Study: 30485924

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus casei Shirota (LcS) administered daily for 1 month
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo (skimmed milk without probiotic) administered daily for 1 month
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus casei Shirota (LcS)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo (skimmed milk without probiotic)
Number of subjects: 283
Study: 26407124

Group type: EXPERIMENTAL
Intervention: pirfenidone tablets (0.4 g) with food
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: pirfenidone tablets (0.4 g) with grapefruit juice
Number of subjects: 12

Group type: COMPARATOR
Intervention: fasted group (control)
Number of subjects: 12
Study: 23352729

Group type: EXPERIMENTAL
Intervention: Foot and hand massage
Number of subjects: 80
Study: 22641248

Group type: EXPERIMENTAL
Intervention: VASS prosthesis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard suction socket system prosthesis
Number of subjects: 20
Study: 22529513

Group type: EXPERIMENTAL
Intervention: 8-week interval training program (60-79% HR max reserve) for 45-60 minutes
Number of subjects: 245

Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 245
Study: 17697908

Group type: EXPERIMENTAL
Intervention: Rupatadine 20 mg under fed conditions
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rupatadine 20 mg under fasting conditions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rupatadine 20 mg under both conditions
Number of subjects: 24
Study: 16120152

Group type: EXPERIMENTAL
Intervention: Dead Sea salt balneophototherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Narrowband ultraviolet B monotherapy
Number of subjects: 60
Study: 12099395

Group type: EXPERIMENTAL
Intervention: Increased plasma fatty acids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased lipoprotein (a)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased acyl carnitine levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased urinary total and free acyl carnitine excretion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decreased plasma free carnitine levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation with duration of DM or HbA1c
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recommendation for plasma free carnitine determinations
Number of subjects: 0
Study: 10655708

Group type: EXPERIMENTAL
Intervention: Irradiation in breast conservation therapy (BCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Boost irradiation to the tumor bed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irradiation to lymph node areas
Number of subjects: 0
Study: 7755528

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Guided mastery therapy
Number of subjects: 52